Last updated: August 10, 2026
Dimethicone 350 is a high-viscosity polydimethylsiloxane, generally identified by a kinematic viscosity of approximately 350 centistokes. It is used in pharmaceutical and healthcare products as a skin protectant, emollient, lubricant, antifoaming agent, and formulation aid. The market is fragmented across silicone manufacturers, specialty excipient suppliers, contract formulators, and regional distributors.
Standalone revenue data for “Dimethicone 350” is not publicly disclosed by major suppliers. Financial analysis therefore depends on pharmaceutical-grade silicone volumes, broader dimethicone sales, medical and personal-care demand, capacity utilization, raw-material costs, and supplier pricing.
What is Dimethicone 350 used for in pharmaceutical products?
Dimethicone 350 is used primarily in topical and semisolid formulations. Its high viscosity creates a persistent, water-resistant film on the skin and can improve spreadability, lubricity, sensory characteristics, and barrier performance.
Main pharmaceutical applications
| Application |
Function of Dimethicone 350 |
Commercial relevance |
| Skin protectants |
Forms a water-repellent barrier and reduces transepidermal water loss |
Core pharmaceutical use |
| Creams and ointments |
Emollient, lubricant, and texture modifier |
High-volume topical segment |
| Barrier creams |
Supports protection against moisture, irritants, and friction |
Used in dermatology and institutional care |
| Wound and incontinence products |
Reduces skin contact with moisture and irritants |
Stable demand from healthcare channels |
| Oral and liquid formulations |
Antifoaming or defoaming aid in selected products |
Smaller than topical demand |
| Medical devices |
Lubrication and surface treatment |
Higher qualification requirements |
| Cosmetic-pharmaceutical hybrids |
Slip, conditioning, and sensory enhancement |
Expands the addressable market |
Dimethicone 350 should not be confused with simethicone. Simethicone is normally a mixture of polydimethylsiloxane and finely divided silicon dioxide and is used as an antiflatulent. Dimethicone 350 is a defined viscosity grade of silicone fluid and is generally used as an excipient or topical active ingredient depending on the formulation and regulatory status.
How large is the Dimethicone 350 market?
The precise global market size cannot be isolated from public filings because suppliers report silicone fluids, healthcare silicones, specialty chemicals, or performance materials at broader product-family levels.
Market structure
The relevant addressable market consists of four overlapping segments:
- Pharmaceutical-grade dimethicone and silicone fluids.
- Medical-grade silicone materials.
- Topical pharmaceutical and dermatological excipients.
- Personal-care and cosmetic dimethicone grades.
Pharmaceutical consumption is smaller than personal-care consumption but has higher qualification barriers and typically better price realization. The same underlying silicone chemistry can be sold into multiple grades, but pharmaceutical customers often require separate documentation, change-control procedures, traceability, and supplier audits.
Demand characteristics
Demand is driven by:
- Growth in topical dermatology and barrier-care products.
- Expansion of generic creams, ointments, lotions, and gels.
- Increased use of skin-protection products in hospitals and long-term care.
- Private-label and over-the-counter dermatology products.
- Medical-device and wound-care manufacturing.
- Substitution of mineral oils and petrolatum in selected formulations.
- Demand for lower-irritancy, non-occlusive or semi-occlusive sensory profiles.
Demand is less sensitive to discretionary consumer spending when Dimethicone 350 is used in prescription, hospital, wound-care, or institutional products. Cosmetic demand is more exposed to retail conditions and brand inventory cycles.
Which companies supply pharmaceutical-grade Dimethicone 350?
The principal competitive set includes large silicone manufacturers and specialist medical-material suppliers. Exact availability depends on grade, pharmacopeial compliance, packaging, manufacturing site, and regional registration.
Major supplier groups
| Supplier group |
Relevant capabilities |
Competitive position |
| Dow |
Silicone fluids, healthcare and pharmaceutical materials, global technical support |
Broad scale and multinational qualification infrastructure |
| Wacker Chemie |
ELASTOSIL and related silicone materials, medical and pharmaceutical supply capabilities |
Strong European manufacturing and technical position |
| Shin-Etsu Chemical |
Silicone fluids and specialty silicone materials |
Broad silicone chemistry and Asian manufacturing base |
| KCC and regional silicone producers |
Silicone fluids and industrial grades |
Cost competition, particularly outside regulated supply chains |
| Specialty medical silicone suppliers |
High-purity fluids, elastomers, and device materials |
Strong in medical-device qualification and custom specifications |
| Regional distributors |
Local inventory, repackaging, and regulatory support |
Important for smaller pharmaceutical customers |
A supplier may offer 350 cSt silicone fluid for industrial, cosmetic, medical, and pharmaceutical use under different product codes. A buyer cannot assume that a non-pharmaceutical 350 cSt grade is interchangeable with a pharmacopeial or validated pharmaceutical grade.
What regulatory status applies to Dimethicone 350?
Dimethicone has established regulatory use in the United States and other major markets, but the regulatory status depends on whether it is used as an active ingredient or inactive ingredient.
FDA status
Dimethicone is recognized in the U.S. over-the-counter skin-protectant framework. FDA regulations identify dimethicone as an active ingredient for certain skin-protectant products, subject to concentration, labeling, and formulation conditions under the applicable monograph framework.[1]
For excipient use, FDA’s Inactive Ingredient Database provides product-specific evidence of prior use. The database does not create a universal approval for every viscosity grade, concentration, route, or dosage form. Sponsors must assess whether the proposed use is supported by prior precedent or requires additional justification.[2]
Pharmacopeial and quality considerations
Commercial pharmaceutical supply can require:
- USP-NF or equivalent compendial compliance.
- Identity and viscosity testing.
- Limits on volatile matter and impurities.
- Heavy-metal or elemental-impurity controls where applicable.
- Microbiological controls for the finished formulation.
- Lot traceability and certificate-of-analysis documentation.
- Change-notification commitments.
- Packaging compatibility and extractables assessment.
Dimethicone 350 is not automatically interchangeable with dimethicone of another viscosity. Viscosity affects processing, spreadability, film formation, emulsion behavior, filling performance, and final product sensory properties.
What are the main market dynamics for Dimethicone 350?
The market is shaped by qualification costs, silicone feedstock economics, formulation performance, and supplier concentration.
1. Qualification creates switching costs
Pharmaceutical customers generally do not switch silicone-fluid suppliers solely on price. A supplier change can require:
- Comparative raw-material testing.
- Stability studies.
- Process revalidation.
- Regulatory documentation updates.
- Packaging and compatibility review.
- Customer notification or approval.
- New supplier audits.
These costs give incumbent suppliers pricing protection after qualification.
2. Supply is linked to silicone-chain economics
Dimethicone is produced from silicone intermediates, principally within the polydimethylsiloxane value chain. Cost exposure includes:
- Silicon metal.
- Chlorosilanes and siloxane intermediates.
- Electricity and natural gas.
- Specialty purification and packaging.
- Freight and hazardous-material logistics.
- Compliance and quality-control overhead.
Energy prices and regional manufacturing costs can influence supplier margins. Large integrated silicone producers generally have better control over upstream economics than distributors or smaller formulators.
3. Regional supply chains affect availability
North America and Europe place greater emphasis on documented pharmaceutical quality systems, regulatory change control, and supply continuity. Asian suppliers can offer cost advantages and growing technical capability, but customer acceptance depends on audit history, documentation, local regulatory support, and consistency of supply.
The commercial risk is highest when a pharmaceutical manufacturer relies on a single qualified site or distributor for a narrow viscosity grade.
4. Formulation substitution is possible but limited
Potential substitutes include:
- Petrolatum.
- Mineral oil.
- Other dimethicone viscosities.
- Cyclomethicone or volatile silicones in non-pharmaceutical applications.
- Polymeric emollients.
- Hydrocarbon or ester-based barrier agents.
- Silicone elastomer gels.
Substitution is constrained by differences in film persistence, sensory profile, occlusivity, emulsion stability, skin feel, processing behavior, and regulatory precedent. A lower-viscosity dimethicone may improve spreadability but reduce substantivity. A higher-viscosity grade may increase barrier performance but complicate mixing and filling.
How does Dimethicone 350 compare with other dimethicone grades?
| Attribute |
Low-viscosity dimethicone |
Dimethicone 350 |
High-viscosity dimethicone |
| Spreadability |
High |
Moderate |
Lower |
| Film persistence |
Lower |
Moderate to high |
High |
| Processing ease |
Generally easier |
Balanced |
More difficult |
| Barrier performance |
Moderate |
Strong |
Strongest |
| Sensory profile |
Light, less substantive |
Smooth and persistent |
More occlusive or tacky |
| Typical use |
Lotions, sprays, light creams |
Creams, ointments, barrier products |
Specialty ointments and high-barrier systems |
| Switching risk |
Product-dependent |
Materially formulation-dependent |
Often high due to rheology |
Dimethicone 350 occupies a middle-to-high viscosity position that supports barrier products without the processing burden of very high-viscosity silicone fluids.
What is the financial trajectory for Dimethicone 350?
The likely financial trajectory is stable-to-moderate growth in pharmaceutical applications, with stronger growth in selected medical, dermatology, and barrier-care niches than in mature mass-market personal-care products.
Revenue drivers
Revenue growth can come from:
- Higher volume of topical generic medicines.
- Increased dermatology and wound-care manufacturing.
- New barrier creams and skin-protection products.
- Regional pharmaceutical production expansion.
- Premium pharmaceutical-grade documentation.
- Medical-device applications using qualified silicone materials.
- Supplier price increases linked to energy, logistics, and quality costs.
Margin drivers
Margins are likely to be higher for:
- Pharmaceutical-grade material.
- Validated medical grades.
- Small-volume, high-documentation supply.
- Custom packaging and controlled distribution.
- Products covered by long-term supply agreements.
Margins are likely to be lower for:
- Industrial-grade material.
- Distributor-led commodity transactions.
- Large-volume personal-care contracts.
- Spot purchases with multiple qualified suppliers.
- Regions with aggressive local competition.
Financial risk factors
| Risk |
Impact on Dimethicone 350 economics |
| Silicone intermediate price volatility |
Can compress margins or force price increases |
| Plant outages |
May create allocation, qualification, and inventory pressure |
| Regulatory change |
Raises documentation and testing costs |
| Customer consolidation |
Increases buyer negotiating power |
| Single-source qualification |
Raises supply risk for pharmaceutical customers |
| Substitution by other emollients |
Limits pricing power in noncritical formulations |
| Weak consumer demand |
Reduces cosmetic and private-label volumes |
| Freight disruption |
Increases landed cost for regional buyers |
Public supplier disclosures generally do not identify Dimethicone 350 as a separate reporting line. The best financial indicators are segment results for healthcare, specialty silicones, performance materials, and medical applications.
What patent protection covers Dimethicone 350?
Dimethicone 350 is a mature chemical material and does not normally depend on a product-specific composition patent for market exclusivity.
Patent and exclusivity position
- The underlying polydimethylsiloxane chemistry is mature.
- No Orange Book exclusivity applies to Dimethicone 350 as an excipient.
- Generic drug sponsors are not normally blocked from using the material by a Dimethicone 350 patent.
- Formulation patents may cover a specific cream, ointment, gel, delivery system, or therapeutic method.
- Manufacturing patents may cover purification, functionalization, packaging, or silicone-containing medical devices.
- Supplier know-how may remain commercially important even when the chemical composition is off-patent.
The relevant intellectual-property barriers are usually formulation-specific and operational rather than molecule-specific. A pharmaceutical company may hold patents on a composition containing dimethicone, but that does not confer exclusivity over Dimethicone 350 itself.
What generic entry risks exist for Dimethicone 350-containing products?
Generic entry risk depends on the finished product, not the excipient alone.
Low-barrier products
Generic competition is usually easier for:
- Simple topical creams.
- Standard skin-protectant ointments.
- Products without complex delivery systems.
- Formulations using widely available dimethicone grades.
- Products with limited clinical differentiation.
Higher-barrier products
Entry can be slower when the product has:
- A complex emulsion or multilayer structure.
- Narrow viscosity or particle-size specifications.
- Device-drug combination characteristics.
- Difficult-to-reproduce sensory or spreading properties.
- Stability sensitivity to silicone grade.
- Proprietary packaging or delivery hardware.
- Method-of-use or formulation patents.
A supplier’s commercial advantage comes from qualification, consistency, documentation, and supply reliability. It does not come from statutory exclusivity over the excipient.
How should investors assess Dimethicone 350 exposure?
Dimethicone 350 is best analyzed as a niche specialty-material input rather than an independent pharmaceutical asset.
Key diligence metrics
Investors and procurement teams should track:
- Revenue exposure to pharmaceutical and medical customers.
- Share of sales from validated or compendial grades.
- Number of qualified manufacturing sites.
- Customer concentration.
- Contract duration and price-adjustment clauses.
- Inventory coverage and safety-stock requirements.
- Raw-material pass-through mechanisms.
- Regulatory audit performance.
- Product-change notification history.
- Share of volume sold through distributors.
- Capacity utilization for silicone-fluid production.
- Gross-margin differences between pharmaceutical and industrial grades.
The strongest commercial position belongs to suppliers with integrated silicone production, multiple qualified sites, pharmaceutical documentation, and long-term customer relationships.
What is the outlook for Dimethicone 350 through the medium term?
The medium-term outlook is positive but measured. Pharmaceutical demand should remain resilient because Dimethicone 350 is used in established topical and barrier-care formats with recurring production volumes. Growth is more likely to come from volume expansion, geographic penetration, and medical applications than from significant price inflation.
The principal constraints are mature chemistry, substitution in simpler formulations, limited standalone market visibility, and the ability of customers to qualify alternative dimethicone grades or suppliers. Premium pricing should persist where documentation, consistency, and regulatory support reduce customer risk.
Key Takeaways
- Dimethicone 350 is a 350 cSt polydimethylsiloxane grade used mainly in topical pharmaceutical and healthcare formulations.
- Its main functions are barrier formation, emollience, lubrication, texture control, and selected antifoaming applications.
- Public companies do not generally disclose revenue specifically for Dimethicone 350.
- The market is more defensible in pharmaceutical-grade and medical applications than in commodity personal care.
- Supplier qualification, documentation, and supply continuity create switching costs.
- The material itself has no meaningful Orange Book or molecule-level exclusivity.
- Formulation patents, medical-device patents, and manufacturing know-how can create product-specific barriers.
- The financial outlook is stable to moderately growing, with margins supported by regulated-grade supply and specialized customer qualification.
- Key risks are silicone feedstock costs, plant interruptions, customer consolidation, and substitution by other emollients.
FAQs
Is Dimethicone 350 the same as simethicone?
No. Dimethicone 350 is a viscosity-defined polydimethylsiloxane fluid. Simethicone generally contains polydimethylsiloxane combined with silicon dioxide and is used primarily as an antiflatulent.
Can pharmaceutical manufacturers substitute another dimethicone viscosity for 350 cSt?
Sometimes, but the substitution can alter spreading, film formation, emulsion stability, processing, filling, and product performance. Comparative development and regulatory assessment are normally required.
Does Dimethicone 350 require an FDA-approved supplier?
FDA approves finished drug products rather than universally approving an excipient supplier. The supplier and material must meet the finished-product sponsor’s quality, regulatory, and qualification requirements.
Is Dimethicone 350 exposed to biosimilar competition?
No direct biosimilar risk applies. Dimethicone 350 is a chemical excipient and is not a biologic drug. Its demand can benefit indirectly from growth in biologic manufacturing only where silicone materials are used in medical devices, processing equipment, or topical products.
Are Dimethicone 350 prices publicly reported?
Generally no. Pricing is usually negotiated through direct supply contracts or specialty-chemical distributors. Contract terms depend on grade, volume, packaging, region, qualification status, and raw-material escalation provisions.
References
- U.S. Food and Drug Administration. (2023). Skin protectant drug products for over-the-counter human use: 21 C.F.R. Part 347. Electronic Code of Federal Regulations.
- U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
- United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.
- Rowe, R. C., Sheskey, P. J., & Quinn, M. E. (Eds.). (2009). Handbook of pharmaceutical excipients (6th ed.). Pharmaceutical Press.
- Dow. (2024). Silicone fluids and healthcare materials product information. Dow Inc.
- Wacker Chemie AG. (2024). Silicone fluids and healthcare product information. Wacker Chemie AG.
